ArticleCellular and molecular life sciences : CMLS2026
Mesenchymal stem cell-derived exosomes alleviate post-resuscitation brain injury by inhibiting neuronal ferroptosis partly via the PRMT1/SLC7A11/GPX4 pathway.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPost-resuscitation brain injury is the main contributor to the death and disability of cardiac arrest (CA) victims. Neuronal ferroptosis is involved in the pathogenesis of brain injury after resuscitation, which becomes an effective therapeutic target. Recent studies demonstrated that mesenchymal stem cell-derived exosomes (MSC-Exo) were a promising approach for the alleviation of regional cerebral ischemia reperfusion injury; however, its effectiveness in post-resuscitation brain injury remains to be investigated. In this study, we investigated whether MSC-Exo could alleviate post-resuscitation brain injury by inhibiting neuronal ferroptosis and its regulatory mechanism. METHODS AND
resultsIn vivo, a clinically relevant swine model of CA and resuscitation was established. In parallel, SH-SY5Y neuronal cells exposed to hypoxia/reoxygenation (H/R) were used as the in vitro model. We found that MSC-Exo administration provided potent protection of neuronal cells against H/R injury in vitro, and effectively alleviated brain injury after CA and resuscitation in vivo. Furthermore, we showed that the protective effects of MSC-Exo administration were associated with the upregulation of protein arginine methyltransferase 1 (PRMT1), solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4) expression, and subsequent inhibition of neuronal ferroptosis in in vitro and in vivo studies. Mechanistically, MSC-Exo administration promoted the recovery of PRMT1 expression, and then the latter bound to the promoter of SLC7A11 and enhanced its transcriptional activity after H/R injury in neuronal cells. Additionally, the miR-320a-3p/tripartite motif-containing 21 (TRIM21) axis was a possible mechanism by which MSC-Exo administration activated the PRMT1/SLC7A11/GPX4 pathway in vitro.
conclusionsMSC-Exo administration effectively alleviated post-resuscitation brain injury after CA and resuscitation, which was related to the inhibition of neuronal ferroptosis partly through the activation of PRMT1/SLC7A11/GPX4 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.